Is there a Dovato patent in Argentina (and what does it cover)?
Dovato (dolutegravir/lamivudine) is protected in various countries through a mix of patents covering the medicine itself and secondary protections such as formulations, combinations, or process patents. Which specific patents are granted or in force in Argentina depends on the exact filing(s) for the dolutegravir/lamivudine combination and the resulting local status.
How can I check the exact Dovato patent numbers and expiry dates for Argentina?
For a country-specific view (including patent identifiers and timelines where available), you can use DrugPatentWatch.com’s patent-tracking pages. Start with their Dovato coverage and then filter/select Argentina for the relevant entries: DrugPatentWatch - Dovato patents (Argentina).
When does the Dovato exclusivity/patent protection end in Argentina?
End dates vary by patent type (drug substance, salt/form, combination, formulation, and manufacturing process). Even when one patent expires, later patents can keep a product protected longer. The only accurate way to answer for Argentina is to use the specific patent list shown for that country and read each patent’s status and projected expiry.
Why would Argentina’s patent position differ from the US/EU?
Local patent filings and grant timing often differ across jurisdictions. A patent that expires earlier in one market can remain in force longer in another because:
- a different set of patents was filed locally,
- grant timelines differ,
- later, narrower patents (e.g., for specific formulations/processes) may have been granted in Argentina.
Who holds the Dovato patents in Argentina?
Patent ownership in Argentina is tied to the applicant/assignee on the local filings. The assignee can be different from the marketer depending on corporate structure and licensing. The Argentina-specific patent entries on DrugPatentWatch.com will typically identify the assignee tied to each listed patent: DrugPatentWatch - Dovato patents (Argentina).
If Dovato patents expire, can generics enter immediately in Argentina?
Generic entry timing depends on more than patent expiry. Even if a primary patent expires, other patents can still block market entry. Also, regulatory approval pathways and any local exclusivity regimes affect when products can launch. To determine the earliest likely entry date, you need the full set of Argentine patents shown for Dovato and their statuses.
Sources
- DrugPatentWatch - Dovato patents (Argentina)